Activation of the FLT3 receptor tyrosine kinase (RTK) due to length mutations in the juxtamembrane domain (JM) are found in 20-25% of AML [2] [3] [4] [5] [6] [7] . In addition, point mutations and deletions of codons 835/836 of FLT3 which are located in the activation loop (A-loop) of the protein tyrosine kinase (PTK) domain, have been described in about 7% of all AML 8, 9 .
FLT3 has a high homology to other class III RTK and plays an important role in the proliferation of hematopoietic progenitors and AML blast cells [10] [11] [12] . Functionally, mutations in the JM region and also in the A-loop result in a constitutively active FLT3 kinase which confers IL-3 independent growth in Ba/F3 cells and activates the MAPK and STAT5 pathways [13] [14] [15] . In the murine bone marrow transplantation model and in transgenic animals active FLT3 mutants induce a myeloproliferative disease, but not acute leukemia which shows that probably additional genetic alterations are necessary for the clinical phenotype in FLT3 -LM positive AML 16, 17 .
In the present study we describe a recurrent activating length mutation in the activation loop of FLT3 in two patients with AML. The cytogenetic analyses showed the karyotype:
46,XX,der (7)t(1;7)(q25;q22) [13] /46,XX [2] . After treatment with a high dose AraC based regimen, the patient died 4 weeks later with no response to therapy. Patient #2, a 76 year old male was diagnosed with AML FAB M6 with the following cytogenetic findings:
44,X,-Y,der(7)t(7;8)(q22;?),t(8;11)(q11;q11),+11,der (12) /46,XY [11] . In this patient the peripheral leukocyte count was 1,570/µl and the percentage of bone marrow blasts was 20%. A low dose AraC and idarubicin containing chemotherapy resulted in a complete remission, but an early relapse occurred and the patient died after 3 months of diagnosis.
Cytogenetics: Cytogenetic G-banding analysis was performed with standard methods 18, 19 .
PCR:
Isolation of mononucleated leukemic cells, mRNA/DNA extraction, reverse transcription and PCR was performed as described previously Screening for further mutations: Screening for MLL-PTD, FLT3-LM, NRASmutations, FLT3D835 and CKITD816 were performed as has been described previously 1, 5, 20 .
Antibodies:
The following antibodies were used: anti-FLT3/flk2 (S18, sc-480, Santa
Cruz, Heidelberg, Germany), anti-PY (PY99, Santa Cruz). expression, immunoprecipitation and Western-blot analysis were performed as described previously 21 .
In vitro mutagenesis:

RESULTS AND DISCUSSION
We used a PCR-based method to screen for mutations of codons D835/836 in patients with AML. After gel electrophoresis of the amplification products from exon 20 we observed an additional PCR fragment which was slightly larger than the PCR product of the wildtype allele in two patients (figure 1B). RT-PCR was repeated more than ten times with different aliquots of RNA as well as cDNA and always gave the same results. Sequencing revealed an insertion of 6 nucleotides between the codons S840 and N841 just five amino acids (AA) downstream of D835. These nucleotides generated a BamHI restriction site which was confirmed by BamHI digestion and gel electrophoresis ( figure 1C ). The mutation resulted in the insertion of a glycine and a serine between AA 840 and 841 of FLT3 ( figure 1D ). For patient 1 a DNA sample was available and the mutation could be shown also at the genomic level by PCR, confirming the presence of the mutation ( Figure 1B ). The respective mutation was not detected in further 357 unselected AML pts. Additional screening for frequent genetic mutations in these two patients showed no further activating mutations of FLT3, NRAS, CKIT or MLL ( figure 1A ).
We generated FLT3-840GS and FLT3-ITD expressing Ba/F3 cells. In Western-blot analyses, the FLT3-840GS and the FLT3ITD receptors were hyperphosphorylated compared to the FLT3WT receptor ( figure 2B ). As shown in figure 2A , the FLT3-840GS
as well as FLT3ITD expressing Ba/F3 cells grew factor-independently, whereas mockand FLT3WT expressing cells were unable to proliferate in the absence of IL-3. Activating mutations of the FLT3 gene provide an essential anti-apoptotic and proproliferative signal in primary AML cells and cell lines 13, 14, 22 . Our results clearly indicate that the FLT3840-GS mutant is hyperphosphorylated on tyrosine residues and induces IL-3 independent growth in Ba/F3 cells. These in vitro data underline the pathophysiologic role of this mutant for the leukemic phenotype in patients with AML. Although the FLT3-840GS is probably a rare mutation, it clearly shows that activating mutations other than the FLT3-LM in the JM domain and FLT3D835/836 in the kinase domain exist in AML. These findings are of significant clinical importance since activating FLT3 mutations could represent selective and specific molecular target structures for therapeutical strategies using PTK inhibitors in AML 23, 24 .
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